Solid Biosciences (NASDAQ:SLDB) stock is rising higher today as investors prepare for an update from the company later this week.
Solid Biosciences will be providing an update on “long-term data from Patients 4-6 in the ongoing IGNITE DMD Phase I/II clinical trial of SGT-001 in patients with Duchenne.” It will present this data at the World Muscle Society 2021 Virtual Congress.
The World Muscle Society 2021 Virtual Congress is taking place from Sept. 20 to the 24th. Solid Biosciences’ presentation is set to take place on Sept. 23, which is Thursday.
An oral session including Vamshi Rao, MD, Attending Physician, Neurology, Lurie Children’s Hospital of Chicago and Assistant Professor of Pediatrics (Neurology and Epilepsy), Northwestern University Feinberg School of Medicine, as well as an unnamed Ignite DMD clinical investigator will go over the results.
Solid Biosciences notes that the presentation will begin at 9:00 a.m. Eastern Time. Anyone that wants to listen in must first sign up to attend the World Muscle Society 2021 Virtual Congress. You can do so at this link.
Holders of SLDB stock are excited about the upcoming news as heavy trading takes place today. As of this writing, more than 7 million shares of the stock have changed hands. For the record, the company’s daily average trading volume is closer to 560,000 shares.
SLDB stock was up 13.2% as of Tuesday afternoon.
We’ve got more recent stock news worth looking into below!
The latest stock market news is all wrapped up in one place for investors. That includes what’s happening with Luckin Coffee (OTCMKTS:LKNCY), Universal Music Group (AMS:UMG), and Rewalk Robotics (NASDAQ:RWLK) shares today. You can get those details at the following links!
More Tuesday Stock Market News
- LKNCY Stock: Why Luckin Coffee Shares Are Heating Up Today
- Universal Music Group IPO: 8 Things for Potential UMG Stock Investors to Know as Shares Debut
- RWLK Stock Short-Squeeze Watch: What to Know as ReWalk Robotics Investors Burn the Shorts
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed